The Ultimaster Nagomi™ coronary stent is designed to navigate the complexities of every procedure for optimal outcomes for/with every patient.^4,5

You can tackle any procedure with ease, adapting and conforming to the lenght and contours of vessels^2,3,6,7,8.

Even in the most challenging anatomy, smooth trackability⁴ and reliable overexpansion³ allow for excellent maneuverability ^5.

This Sirolimus eluting coronary stent system provides the versatility and flexibility you need to deliver the best possible results^{9, 10, 11}. Add a new level of innovation to your practice with the Ultimaster Nagomi sirolimus eluting coronary stent system.^{9, 10, 11}

Improved Coronary Stent Design^1,2

Three dedicated platforms specifically engineered to address the unique requirements of each vessel size^1,2.

• Shortened strut and band width in stent diameters ranging from 2 mm to 2.5 mm designed to enhance flexibility.^1,2,6

• New 10-crown design for large vessel

  • designed to support optimised stent apposition, even in large bifurcation, including left main trunk.^1,2,7
  • Provides improved expansion capability with uniform vessel coverage compared to an 8-crown design.^1,2,3

Expanded  Size Lineup^1,2,3 to Address Various Lesion Coverage Needs

Improved  Overexpansion Capability³ for Large Vessels

• 10-crown design for an improved expansion in large vessels.^1,2,3
• Optimised overexpansion capability up to 6.25 mm for stents with nominal diameters between 3.50 mm and 4.50 mm.³

Excellent Deliverability^4,5

• Improved hydrophilic coating for enhanced deliverability.^4,5
• Delivery balloon with a nominal pressure of 11 atm to aid better stent apposition^7,8
• Catheter features an expanded  inner lumen to support fast deflation.^12,13

Drug and Polymer Technology Derived from the Ultimaster™ Family

The Ultimaster Nagomi™ coronary stent incorporates the same abluminal gradient bioresorbable coating technology developed within the Ultimaster™ family.

• Designed to maintain polymer integrity even during overexpansion, allowing for a consistent and optimised sirolimus drug dose of 3.9 μg/mm of stent length^1,2,14,15
• Drug release and polymer resorption occur simultaneously within 3–4 months, to match the procedure-triggered biological response⁹